// App-Quantinova.ai

308 : Nivolumab + cabozantinib (NIVO+CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER.

Researchers

Presenter

  • Robert J. Motzer

Principal Investigators

  • Thomas Powles

  • Mauricio Burotto

  • Maria Teresa Bourlon

  • James J Hsieh

  • Marco Maruzzo

  • Amishi Yogesh Shah

  • Cristina Suarez

  • Carlos H. Barrios

  • Martin Eduardo Richardet

  • Camillo Porta

  • Jeffrey C. Goh

  • Yoshihiko Tomita

  • Jens Bedke

  • Joshua Zhang

  • Burcin Simsek

  • Christian Scheffold

  • Saurabh Gupta

  • Andrea B. Apolo

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

  • Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

  • Bradford Hill Research Center, Santiago, Chile

  • Urologic Oncology Clinic, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, DF, Mexico

  • Alvin J Siteman Cancer Center at Washington University School of Medicine, St. Louis, MO

  • Medical Oncology Unit 1, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy

  • 1.MD Anderson Cancer Center, Houston, TX

  • Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus,Barcelona,Spanien

  • Hospital San Lucas da PUC, Porto Alegre, Brazil

  • Fundacion Richardet Longo, Instituto Oncologico de Cordoba, Cordoba, Argentina

  • University of Bari Aldo Moro, Bari, Italy

  • Royal Brisbane and Women's Hospital, Herston and University of Queensland, Queensland, Australia

  • Nigata University Graduate School of Medical and Dental Sciences, Japan

  • Eberhard Karls University, Tubingen, Germany

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Exelixis, Alameda, CA

  • National Human Genome Research Institute, National Institutes of Health, Bethesda, MD

Locations

  • United States

  • United Kingdom

  • Chile

  • Mexico

  • Italy

  • Spain

  • Brazil

  • Argentina

  • Australia

  • Japan

  • Germany

Companies

  • Exelixis, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Metastatic Renal Cell Cancer

  • Signet ring cell carcinoma

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Cabozantinib

  • Nivolumab

  • Sunitinib

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Open Label

Phase

  • III

Study Id's

  • NCT03141177

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved